CAR T-Cell Therapy for Glioblastoma
Trial Summary
What is the purpose of this trial?
This phase I trial investigates the side effects of brain tumor-specific immune cells (IL13Ralpha2-CAR T cells) in treating patients with leptomeningeal disease from glioblastoma, ependymoma, or medulloblastoma. Immune cells are part of the immune system and help the body fight infections and other diseases. Immune cells can be engineered to destroy brain tumor cells in the laboratory. IL13Ralpha2-CAR T cells is brain tumor specific and can enter and express its genes in immune cells. Giving IL13Ralpha2-CAR T cells may better recognize and destroy brain tumor cells in patients with leptomeningeal disease from glioblastoma, ependymoma or medulloblastoma.
Do I need to stop my current medications for the trial?
Yes, you will need to stop taking chemotherapy, endocrine therapy, and radiation one week before and during the first 4 cycles of the study.
What data supports the effectiveness of the treatment IL13Ralpha2-CAR T cells for glioblastoma?
Research shows that IL13Ralpha2-CAR T cells can specifically target and kill glioblastoma cells that have a certain marker (IL13Ralpha2) without affecting normal brain cells. In a study, a patient with glioblastoma experienced tumor shrinkage after receiving this treatment, and the positive effects lasted for several months.12345
Is CAR T-Cell Therapy targeting IL13Rα2 safe for humans?
What makes IL13Ralpha2-CAR T-cell therapy unique for treating glioblastoma?
IL13Ralpha2-CAR T-cell therapy is unique because it specifically targets the IL13Rα2 protein, which is highly expressed in glioblastoma but not in normal brain tissue, reducing the risk of harming healthy cells. This therapy involves genetically modifying T cells to recognize and attack glioblastoma cells, offering a promising approach for patients with this aggressive cancer.23456
Research Team
Lisa A. Feldman
Principal Investigator
City of Hope Medical Center
Eligibility Criteria
This trial is for patients with leptomeningeal disease from glioblastoma, ependymoma, or medulloblastoma. They must have a life expectancy of at least 8 weeks, be able to tolerate certain medical procedures and medications, not require dialysis or supplemental oxygen, and agree to use birth control. Those with other active cancers or infections like hepatitis B/C or HIV can't join.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive IL13Ralpha2-CAR T cells ICV over 5 minutes on day 1. Treatment repeats every 7 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- IL13Ralpha2-CAR T Cells (CAR T-cell Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
Robert Stone
City of Hope Medical Center
Chief Executive Officer since 2014
Juris Doctorate from the University of Chicago, Bachelor's degree in Political Science from the University of Redlands
Sumanta (Monty) Pal
City of Hope Medical Center
Chief Medical Officer since 2023
MD
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School